Autolus Therapeutics (AUTL) Income from Continuing Operations: 2016-2024

Historic Income from Continuing Operations for Autolus Therapeutics (AUTL) over the last 9 years, with Dec 2024 value amounting to -$220.7 million.

  • Autolus Therapeutics' Income from Continuing Operations rose 3.63% to -$79.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$224.8 million, marking a year-over-year increase of 16.81%. This contributed to the annual value of -$220.7 million for FY2024, which is 5.89% down from last year.
  • As of FY2024, Autolus Therapeutics' Income from Continuing Operations stood at -$220.7 million, which was down 5.89% from -$208.4 million recorded in FY2023.
  • Over the past 5 years, Autolus Therapeutics' Income from Continuing Operations peaked at -$142.1 million during FY2021, and registered a low of -$220.7 million during FY2024.
  • Its 3-year average for Income from Continuing Operations is -$192.6 million, with a median of -$208.4 million in 2023.
  • As far as peak fluctuations go, Autolus Therapeutics' Income from Continuing Operations rose by 24.91% in 2021, and later tumbled by 39.98% in 2023.
  • Yearly analysis of 5 years shows Autolus Therapeutics' Income from Continuing Operations stood at -$189.3 million in 2020, then increased by 24.91% to -$142.1 million in 2021, then dropped by 4.73% to -$148.9 million in 2022, then slumped by 39.98% to -$208.4 million in 2023, then dropped by 5.89% to -$220.7 million in 2024.